Metraipolis › archive › dc_fbeb390bb49d

Rosetta@home — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Rosetta@home
License (as archived)
CC-BY-SA-4.0
Archived
2026-10-05T23:02:24.326Z
SHA-256 of the archived text
8bf635337d266dbed3f1df3ccaf14577d2e32b1d2e1c588c3fa329fc84046236
Stable URL of this page
https://metraipolis.com/documento/dc_fbeb390bb49d

How to cite

Rosetta@home — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Rosetta@home (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_fbeb390bb49d (Metraipolis archive dc_fbeb390bb49d, sha256 8bf635337d266dbed3f1df3ccaf14577d2e32b1d2e1c588c3fa329fc84046236)
BibTeX
@misc{dcfbeb390bb49d,
  title = {Rosetta@home — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Rosetta@home},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_fbeb390bb49d; sha256 8bf635337d266dbed3f1df3ccaf14577d2e32b1d2e1c588c3fa329fc84046236},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Rosetta@home. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Rosetta@home is a volunteer computing project researching protein structure prediction on the Berkeley Open Infrastructure for Network Computing (BOINC) platform, run by the Baker lab. Rosetta@home aims to predict protein–protein docking and design new proteins with the help of about fifty-five thousand active volunteered computers processing at over 487,946 gigaFLOPS on average as of September 19, 2020. Foldit, a Rosetta@home videogame, aims to reach these goals with a crowdsourcing approach. Though much of the project is oriented toward basic research to improve the accuracy and robustness of proteomics methods, Rosetta@home also does applied research on malaria, Alzheimer's disease, and other pathologies. Like all BOINC projects, Rosetta@home uses idle computer processing resources from volunteers' computers to perform calculations on individual workunits. Completed results are sent to a central project server where they are validated and assimilated into project databases. The project is cross-platform, and runs on a wide variety of hardware configurations. Users can view the progress of their individual protein structure prediction on the Rosetta@home screensaver. In addition to disease-related research, the Rosetta@home network serves as a testing framework for new methods in structural bioinformatics. Such methods are then used in other Rosetta-based applications, like RosettaDock or the Human Proteome Folding Project and the Microbiome Immunity Project, after being sufficiently developed and proven stable on Rosetta@home's large and diverse set of volunteer computers. Two especially important tests for the new methods developed in Rosetta@home are the Critical Assessment of Techniques for Protein Structure Prediction (CASP) and Critical Assessment of Prediction of Interactions (CAPRI) experiments, biennial experiments which evaluate the state of the art in protein structure prediction and protein–protein docking prediction, respectively. Rosetta consistently ranks among the foremost docking predictors, and is one of the best tertiary structure predictors available. With an influx of new users looking to participate in the fight against the COVID-19 pandemic, caused by SARS-CoV-2, Rosetta@home increased its computing power up to 1.7 PetaFlops as of March 28, 2020. On September 9, 2020, Rosetta@home researchers published a paper describing 10 potent antiviral candidates against SARS-CoV-2. Rosetta@home contributed to this research and these antiviral candidates are heading towards Phase 1 clinical trials, which may begin in early 2022. According to the Rosetta@home team, Rosetta volunteers contributed to the development of a nanoparticle vaccine. This vaccine has been licensed and is known as the IVX-411 by Icosavax, which began a Phase I/II clinical trial in June 2021, and GBP510 which is being developed by SK Bioscience and is already approved for a Phase III clinical trial in South Korea. NL-201, a cancer drug candidate that was first cr

Tema degli esploratori: calcolo e infrastrutture (deposito sistematico; categoria «Volunteer computing projects»).
Fonte: Wikipedia in inglese, voce «Rosetta@home» — https://en.wikipedia.org/wiki/Rosetta@home
Wikidata Q898343 (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q898343
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Rosetta@home?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1375287711, consultata il 2026-10-05T22:59:47.855Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: ed07a663cbd3fb69084fec97276b9963d8be276322e55273841c6e35158e394a